<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336138</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/12/0072</org_study_id>
    <nct_id>NCT03336138</nct_id>
  </id_info>
  <brief_title>Application of Telemedicine to the Management of Aggressive Lymphomas</brief_title>
  <acronym>AMA</acronym>
  <official_title>Application of Telemedicine to the Management of Aggressive Lymphomas: a Regional Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the value of AMA in a comparative multicenter
      regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI. This
      study consider that the AMA support should allow a significant improvement of the RDI
      compared to the control group and thus impact the duration without progression. The study
      covers 350 patients recruited from 10 regional centers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-relative intensity (RDI)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>reduction of RDI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>AMA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient with standard follow-up with no specific assistance for ambulatory patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AMA (Assistance for ambulatory patients)</intervention_name>
    <description>telephone follow-up modality</description>
    <arm_group_label>AMA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven,
             with treatment not started

          -  a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin,
             vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab,
             doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP).

          -  Index international prognosis (IPI) measurable (IPI-aa), adjusted for age. Any IPI-aa
             is eligible.

          -  accepting the study

        Exclusion Criteria:

          -  Patient with another type of lymphoma (including transformed follicular forms)

          -  Patient having already started his treatment.

          -  Life expectancy &lt;3 months.

          -  Carcinologic history

          -  Serum positive for HIV or hepatitis B virus (HBV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURENT Guy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LAURENT Guy, MD</last_name>
    <email>laurent.g@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>COMPACI Gis√®le, Nurse</last_name>
    <email>compaci.g@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houyau Philippe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Auch</city>
        <zip>32000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaillant Willy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bayonne Hospital</name>
      <address>
        <city>Bayonne</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Banos Anne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fitoussi Olivier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrero Miguel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Marzet</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schlaifer Daniel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rodez Hospital</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mosser Laurent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tarbes Hospital</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingremont Claire, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suc Etienne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAURENT Guy, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

